AsemconnectVietnam - Imexpharm Pharmaceutical Joint Stock Company (stock code IMP - HOSE) has just announced the situation of production and business activities in 2023.

Accordingly, in 2023, the Company will achieve net revenue of VND1,994 billion, an increase of 21% over the same period and exceeding the yearly plan by 14% thanks to the contribution of 53% from the OTC channel and 42.7% from the ETC channel. Of which, OTC revenue increased by 8% over the same period thanks to efforts to retain customers, expand the network and strong growth of key products. ETC revenue grew 40% over the same period thanks to the recovery of hospitals and expanded product portfolio.
Antibiotics are still IMP's core strength and contribute 74% to total revenue. IMP said that the Company is taking active measures to increase revenue from non-antibiotic drugs.
EU-GMP factories (IMP2, IMP3 and IMP4) with product portfolios targeting the ETC channel contributed higher to revenue and profit thanks to increased operating capacity.
Pre-tax profit in 2023 will reach VND377 billion, up 29% over the same period and exceeding the yearly plan by 8%. EBITDA margin (earnings before interest, taxes and depreciation) in 2023 improved from 22% to 23% thanks to strong revenue growth leading to better economies of scale and higher operating leverage as well as effective cost-saving initiatives.
In 2024, IMP plans to expand MA EU group 1 (product registration number in Europe); global business development; import, technology transfer and innovation initiatives.
N.Nga
Source: VITIC/Tinnhanhchungkhoan